Fig. 5

Change in enthesitis sites with secukinumab 300 mg and 150 mg over week 104 in patients with no enthesitis at baseline. Data presented are as observed. Number of evaluable patients at week 4—90 (300 mg), 78 (150 mg), and 70 (placebo); at week 16—92 (300 mg), 78 (150 mg), and 70 (placebo); and at week 104—83 (300 mg) and 62 (150 mg). ES, enthesitis site; n, number of patients with no enthesitis at weeks 4, 16, and 104